Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Rashid, Ayesha ^a,b   Liu, Caiqiong ^a   Sanli, Toran ^a,b   Tsiani, Evangelia ^c   Singh, Gurmit ^b   Bristow, Robert G ^d   Dayes, Ian ^b   Lukka, Himu ^b   Wright, James ^b   Tsakiridis, Theodoros ^a,b  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c BROCK UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atm; Cell cycle; Clonogenic survival; P21cip1; P53; Radio sensitizers

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN P53; RESVERATROL; ANTINEOPLASTIC AGENT; STILBENE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; CLONOGENIC ASSAY; DNA DAMAGE; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IONIZING RADIATION; MICROSCOPY; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; FLUORESCENCE MICROSCOPY; MALE; METABOLISM; METHODOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; G1 PHASE; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION, IONIZING; STILBENES; TOR SERINE-THREONINE KINASES;

EID: 81255144018     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-144     Document Type: Article

References (43)

1. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010, 28(7):1106-1111. 10.1200/JCO.2009.25.8475, 2834463, 20124169.
2. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002, 296(5573):1655-1657. 10.1126/science.296.5573.1655, 12040186.
3. Rodemann HP, Dittmann K, Toulany M. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 2007, 83(11-12):781-791. 10.1080/09553000701769970, 18058366.
4. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction [see comments]. Nature 1995, 376(6541):599-602. 10.1038/376599a0, 7637810.
5. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997, 7(4):261-269. 10.1016/S0960-9822(06)00122-9, 9094314.
6. Viniegra JG, Martinez N, Modirassari P, Losa JH, Parada Cobo C, Lobo VJ, Luquero CI, Alvarez-Vallina L, Ramon Y, Cajal S, Rojas JM, Sanchez-Prieto R. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 2005, 280(6):4029-4036.
7. Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2007, 10(4):331-339. 10.1038/sj.pcan.4500974, 17471291.
8. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001, 98(20):11598-11603. 10.1073/pnas.181181198, 58775, 11504915.
9. Li Y, Dowbenko D, Lasky LA. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 2002, 277(13):11352-11361. 10.1074/jbc.M109062200, 11756412.
10. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002, 8(10):1136-1144. 10.1038/nm762, 12244303.
11. Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K, Schmidt-Ullrich RK. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 2002, 21(25):4032-4041. 10.1038/sj.onc.1205500, 12037685.
12. Diaz R, Nguewa PA, Diaz-Gonzalez JA, Hamel E, Gonzalez-Moreno O, Catena R, Serrano D, Redrado M, Sherris D, Calvo A. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Br J Cancer 2009, 100(6):932-940. 10.1038/sj.bjc.6604938, 2661786,2661786, 19240717.
13. Steinberg GR, Kemp BE. AMPK in Health and Disease. Physiol Rev 2009, 89(3):1025-1078. 10.1152/physrev.00011.2008, 19584320.
14. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005, 18(3):283-293. 10.1016/j.molcel.2005.03.027, 15866171.
15. Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC, Singh G, Wright J, Tsakiridis T. Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 2010, 78(1):221-229. 10.1016/j.ijrobp.2010.03.005, 20615625.
16. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004, 24(5A):2783-2840.
17. Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ, Argiles JM. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun 1999, 254(3):739-743. 10.1006/bbrc.1998.9916, 9920811.
18. Scarlatti F, Sala G, Ricci C, Maioli C, Milani F, Minella M, Botturi M, Ghidoni R. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett 2007, 253(1):124-130. 10.1016/j.canlet.2007.01.014, 17321671.
19. Zoberi I, Bradbury CM, Curry HA, Bisht KS, Goswami PC, Roti Roti JL, Gius D. Radiosensitizing and anti-proliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Lett 2002, 175(2):165-173. 10.1016/S0304-3835(01)00719-4, 11741744.
20. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH. AMPK-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2009,
21. Kimura Y, Okuda H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr 2001, 131(6):1844-1849.
22. Aziz MH, Nihal M, Fu VX, Jarrard DF, Ahmad N. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 2006, 5(5):1335-1341. 10.1158/1535-7163.MCT-05-0526, 16731767.
23. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55(8):2180-2191. 10.2337/db05-1188, 16873680.
24. Hwang J-T, et al. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathways. Ann NY Acad Sci 2007, 1095(1):441-448. 10.1196/annals.1397.047, 17404056.
25. Sexton E, Van Themsche C, LeBlanc K, Parent S, Lemoine P, Asselin E. Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol Cancer 2006, 5:45. 10.1186/1476-4598-5-45, 1626081, 17044934.
26. Sabolic I, Brown D. Water channels in renal and nonrenal tissues. NIPS 1995, 10:12-17.
27. Bromfield GP, Meng A, Warde P, Bristow RG. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis 2003, 6(1):73-85. 10.1038/sj.pcan.4500628, 12664070.
28. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999, 35(7):403-409. 10.1007/s11626-999-0115-4, 10462204.
29. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008, 9(3):288-296. 10.1016/S1470-2045(08)70073-1, 18308254.
30. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004, 64(24):9152-9159. 10.1158/0008-5472.CAN-04-2727, 15604286.
31. Gescher AJ, Steward WP. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev 2003, 12(10):953-957.
32. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 2007, 12:4839-4854. 10.2741/2432, 17569614.
33. Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, Schiestl B, von Guggenberg E, Neher A, Bonn GK, Huber LA, Lukas P. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 2008, 8(21):4521-4533. 10.1002/pmic.200800113, 18821526.
34. Li L, Ross AH. Why is PTEN an important tumor suppressor?. J Cell Biochem 2007, 102(6):1368-1374. 10.1002/jcb.21593, 17972252.
35. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000, 275(32):24500-24505. 10.1074/jbc.M003145200, 10827191.
36. Hsieh TC, Wu JM. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 1999, 249(1):109-115. 10.1006/excr.1999.4471, 10328958.
37. Rusin M, Zajkowicz A, Butkiewicz D. Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. Mech Ageing Dev 2009, 130(8):528-537. 10.1016/j.mad.2009.06.005, 19559722.
38. Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 2001, 7(5):1466-1473.
39. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, Watson RW. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 2007, 67(15):1641-1653. 10.1002/pros.20653, 17823925.
40. Shih A, Zhang S, Cao HJ, Boswell S, Wu YH, Tang HY, Lennartz MR, Davis FB, Davis PJ, Lin HY. Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol Cancer Ther 2004, 3(11):1355-1364.
41. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23(16):2825-2837. 10.1038/sj.onc.1207528, 15077146.
42. Gurumurthy S, Vasudevan KM, Rangnekar VM. Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 2001, 20(3-4):225-243.
43. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, Slingerland JM, Mills GB. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007, 9(2):218-224. 10.1038/ncb1537, 17237771.